Foxp3 promoter polymorphism (rs3761548) in breast cancer progression: a study from India

• Published in: Tumor biology Vol. 35; no. 4; pp. 3785 - 3791
• Main Authors: Jahan, Parveen, Ramachander, V. R. Vinish, Maruthi, G., Nalini, S., Latha, K. Prasanna, Murthy, T. S. R.
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.04.2014; Springer Nature B.V
• Subjects: Adult; Aged; Biomarkers; Biomedical and Life Sciences; Biomedicine; Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Cancer Research; Disease Progression; Female; Forkhead Transcription Factors - genetics; Genes; Genetic Predisposition to Disease; Genotype; Humans; India; Middle Aged; Neoplasm Staging; Polymorphism; Polymorphism, Genetic; Promoter Regions, Genetic; Research Article; India; Tumor stage; Treg cells; Foxp3; Menopausal history
• ISSN: 1010-4283; 1423-0380
• DOI: 10.1007/s13277-013-1501-9

Breast cancer is the most common female neoplasm that drives the transformation of normal mammary epithelial cells into highly malignant derivatives. Forkhead Box Protein3 (Foxp3), a tumor suppressor/immunomodulatory gene, which controls the function of Treg cells and oncogenes is down regulated in breast cancer. The main aim of the present study is to evaluate the potential influence of Foxp3-3279 C>A polymorphism (rs3761548) and -2383 C>T polymorphism (rs3761549) in 202 breast cancer patients and 130 normal healthy women of Indian origin. The genotypes were determined using ARMS-PCR for rs3761548 and PCR-RFLP method for rs3761549 using specific primers. The results revealed lack of association of these two polymorphisms with breast cancer susceptibility. However, with respect to AA genotype of rs3761548, we found highly significant association with the advanced stage (T3-4) of the tumor (OR = 3.90; 95 % confidence interval (CI) = 1.56–9.70; p  = 0.03). Stratified data also revealed an association of homozygous mutant genotype with advanced stage of tumor in premenopausal women (OR = 4.56; 95 % CI = 1.07–19.38; p  = 0.04) with disease duration of <6 months (OR = 6.10; 95 % CI = 1.80–20.50; p  = 0.002) suggestive of modulating effect of rs3761548 in tumor progression. We conclude that Foxp3 rs37161548 has a potential to be a polymorphic marker for tumor progression in premenopausal breast cancer patients in Indian women.